The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP)

Patrizio Mazza, Carla Minoia, Angela Melpignano, Giuseppe Polimeno, Nicola Cascavilla, Nicola Di Renzo, Giorgina Specchia

Research output: Contribution to journalArticlepeer-review

Abstract

Immune thrombocytopenia (ITP) is a disease which sees one-third of patients failing first and subsequent therapeutic approaches, including splenectomy. Thrombopoietin-receptor agonists (TPO-RAs) are recommended for adults who relapse after splenectomy or who have contraindications for splenectomy. In this multicenter study, a total of 124 patients were retrospectively evaluated: 55 (44.3 %) were treated by romiplostim and 69 (55.6 %) by eltrombopag. Mean age, number of young patients (

Original languageEnglish
Pages (from-to)239-244
Number of pages6
JournalAnnals of Hematology
Volume95
Issue number2
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Immune thrombocytopenia (ITP)
  • Splenectomy
  • Thrombopoietin receptor agonists

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP)'. Together they form a unique fingerprint.

Cite this